80 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
31 Jan 24
Other Events
5:07pm
, which met its primary endpoint for efficacy. Data from the trial were presented at the Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Dec 23
Other Events
7:13am
Society (CTOS) 2023 Annual Meeting.
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: “With this submission, we have completed a critical step
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
or unresectable synovial sarcoma or MRCLS on Thursday November 2nd at the Connective Tissue Oncology Society (CTOS) annual meeting taking place
8-K
zmnhqem17
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
1vkw2v
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
vba1 uhchyrnt
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
ku788gn6jgih2m m48z8
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
cizrtic9
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
8jz 0wu091w6wekz9q
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-99.1
4wgjw8s4zwqv 35i
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
kmuu5v1
9 May 22
Adaptimmune Reports First Quarter Financial Results and Business Update
7:40am